Changchun High-Tech Industry (Group) (000661) Q3 2025 earnings summary

Executive summary

• Revenue for the first three quarters of 2025 was ¥9.81 billion, down 5.60% year-over-year; net profit attributable to shareholders was ¥1.16 billion, down 58.23% year-over-year.

• Significant decline in net profit mainly due to lower performance in key subsidiaries and increased asset impairment losses.

Financial highlights

• Q3 revenue: ¥3.20 billion, down 14.55% compared to the same quarter last year.

• Q3 net profit attributable to shareholders: ¥182 million, down 82.98% year-over-year.

• Operating cash flow for Q3: ¥721.92 million, down 76.68% year-over-year.

• Basic EPS for Q3: ¥0.45, down 83.08% year-over-year.

• Total assets at period end: ¥31.46 billion, up 1.31% from year-end 2024.

Outlook and guidance

• Subsidiary Jinsai Pharma saw revenue rise 0.61% but net profit fell 49.96% year-over-year.

• Baike Biotech revenue dropped 53.76% and posted a net loss of ¥158 million.

• Huakang Pharma revenue fell 5.38% but net profit rose 2.46% year-over-year.

• High-tech Real Estate revenue fell 7.97% with net profit nearly flat.